Therapies for Inborn Errors of Metabolism: What Has the Orphan Drug Act Delivered?-Reference-Cited by-同舟云学术

Therapies for Inborn Errors of Metabolism: What Has the Orphan Drug Act Delivered?

Published:2010-07-01 Issue:1 Volume:126 Page:101-106
ISSN:0031-4005
Container-title:Pediatrics
language:en
Short-container-title:

Author:

Talele Sonali S.¹²,Xu Kui¹,Pariser Anne R.³,Braun M. Miles¹,Farag-El-Massah Sheiren¹⁴,Phillips M. Ian²,Thompson Barry H.⁵,Coté Timothy R.¹

Affiliation:

1. Office of Orphan Products Development and

2. Center for Rare Disease Therapies, Keck Graduate Institute, Claremont, California;

3. Division of Gastroenterology Products, Office of New Drugs, Food and Drug Administration, Silver Spring, Maryland;

4. Department of Social and Administrative Pharmacy Program, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota; and

5. American College of Medical Genetics, Bethesda, Maryland

Abstract

OBJECTIVE: The 1983 US Orphan Drug Act established a process through which promising therapies are designated as orphan products and, later, with satisfactory safety and efficacy data, receive marketing approval and fiscal incentives. We examined accomplishments in drug development for inborn errors of metabolism (IEMs). METHODS: Food and Drug Administration data were used to identify orphan product designations and approvals for IEMs, and the trends for the past 26 years were summarized. Individual clinical development times (CDTs) from filing investigational new drug application to marketing approval were determined. RESULTS: We examined 1956 orphan product designations from 1983 through 2008 and found 93 (4.8%) for IEMs. Of those, 24 (25.8%) received marketing approval. This proportion of approval was significantly (P = .036) higher than that for non-IEM orphan products (17%). Among the IEM products, disorders of complex molecules received the most designations and approvals (61 and 11, respectively). Among the subgroups, lysosomal storage diseases received the most designations and approvals (43 and 9, respectively), whereas mitochondrial diseases (other than fatty acid oxidation disorders) received 7 designations with no approvals. We then examined the CDTs for the approved IEM products and found a median of 6.4 years (range: 2.6–25.1 years). Biological products had significantly shorter CDTs than drugs (mean: 4.6 vs 11.0 years; P = .003). CONCLUSION: For 26 years, the Orphan Drug Act has generated new therapies for IEMs. Why some IEMs have motivated successful drug development and others have not remains enigmatic; yet the needs of IEM patients without treatment are a certainty.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology and Child Health

Link

https://publications.aap.org/pediatrics/article-pdf/126/1/101/1050544/zpe00710000101.pdf

Reference9 articles.

1. Food and Drug Administration. Orphan Drug Act. Available at: www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Overview/ucm119477.htm. Accessed June 27, 2009

2. Food and Drug Administration. Overview: purpose of the Orphan Products Program. Available at: www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/Overview/default.htm. Accessed June 27, 2009

3. Food and Drug Administration. Investigational new drug (IND) or device exemption (IDE) process (CBER). Available at: www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/default.htm. Accessed July 24, 2009

4. Inborn errors of metabolism: the flux from Mendelian to complex diseases;Lanpher;Nat Rev Genet,2006

5. Weiner DL . Pediatrics, inborn errors of metabolism. Available at: http://emedicine.medscape.com/article/804757-overview. Accessed July 20, 2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developing Treatments for Rare Diseases on a Shoestring;GEN Biotechnology;2023-10-01

2. Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public–private partnerships;Journal of Inherited Metabolic Disease;2023-04

3. Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases;GEN Biotechnology;2022-04-01

4. Dialytic Therapy of Inborn Errors of Metabolism in Case of Acute Decompensation;Pediatric Dialysis;2021

5. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in Neonatal Mice;Molecular Pharmaceutics;2020-12-15